Literature DB >> 29113960

Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy.

Peter H Ahn1, Jarod C Finlay1, Shannon M Gallagher-Colombo1, Harry Quon1, Bert W O'Malley2, Gregory S Weinstein2, Ara Chalian2, Kelly Malloy2, Thomas Sollecito3, Martin Greenberg4, Charles B Simone1, Sally McNulty1, Alexander Lin1, Timothy C Zhu1, Virginia Livolsi5, Michael Feldman5, Rosemarie Mick6, Keith A Cengel1, Theresa M Busch7.   

Abstract

BACKGROUND: We report on a Phase 1 trial of photodynamic therapy (PDT) for superficial head and neck (H&N) lesions. Due to known oxygen dependencies of PDT, translational measurements of lesion hemoglobin oxygen saturation (StO2) and blood volume (tHb) were studied for associations with patient outcomes.
METHODS: PDT with aminolevulinc acid (ALA) and escalating light doses was evaluated for high-grade dysplasia, carcinoma-in-situ, and microinvasive carcinomas of the H&N. Among 29 evaluable patients, most (18) had lesions of the tongue or floor of mouth (FOM). Disease was intact in 18 patients and present at surgical margins in 11 patients. In 26 patients, lesion StO2 and tHb was measured.
RESULTS: Local control (LC) at 24 months was 57.5% among all patients. In patients with tongue/FOM lesions LC was 42.7%, and it was 50.1% for those with intact lesions. Lesion tHb was not associated with 3-month complete response (CR), but StO2 was higher in patients with CR. In tongue/FOM lesions, baseline StO2 [mean(SE)] was 54(4)% in patients (n=12) with CR versus 23(8)% in patients (n=6) with local recurrence/persistence (p=0.01). Similarly, for intact disease, baseline StO2 was 54(3)% in patients (n=10) with CR versus 28(8)% in patients (n=5) without CR (p=0.03). In patients with intact disease, higher baseline StO2 associated with 24-month local control (p=0.02).
CONCLUSIONS: Measurement of the physiologic properties of target lesions may allow for identification of patients with the highest probability of benefiting from PDT. This provides opportunity for optimizing light delivery based on lesion characteristics and/or informing ongoing clinical decision-making in patients who would most benefit from PDT.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aminolevulinic acid; Carcinoma-in-situ; Dysplasia; Head and neck; Microinvasive squamous cell carcinoma; Tissue hemoglobin oxygen saturation

Mesh:

Substances:

Year:  2017        PMID: 29113960      PMCID: PMC5866751          DOI: 10.1016/j.pdpdt.2017.10.015

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  39 in total

1.  Non-invasive measurement of the morphology and physiology of oral mucosa by use of optical spectroscopy.

Authors:  A Amelink; O P Kaspers; H J C M Sterenborg; J E van der Wal; J L N Roodenburg; M J H Witjes
Journal:  Oral Oncol       Date:  2007-03-09       Impact factor: 5.337

2.  Predictions and measurements of scattering and absorption over broad wavelength ranges in tissue phantoms.

Authors:  J R Mourant; T Fuselier; J Boyer; T M Johnson; I J Bigio
Journal:  Appl Opt       Date:  1997-02-01       Impact factor: 1.980

3.  Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Authors:  Theresa M Busch; Xiaoman Xing; Guoqiang Yu; Arjun Yodh; E Paul Wileyto; Hsing-Wen Wang; Turgut Durduran; Timothy C Zhu; Ken Kang-Hsin Wang
Journal:  Photochem Photobiol Sci       Date:  2009-10-15       Impact factor: 3.982

4.  Non-invasive measurement of the microvascular properties of non-dysplastic and dysplastic oral leukoplakias by use of optical spectroscopy.

Authors:  A Amelink; H J C M Sterenborg; J L N Roodenburg; M J H Witjes
Journal:  Oral Oncol       Date:  2011-09-13       Impact factor: 5.337

5.  Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Authors:  Peter H Ahn; Harry Quon; Bert W O'Malley; Gregory Weinstein; Ara Chalian; Kelly Malloy; Joshua H Atkins; Thomas Sollecito; Martin Greenberg; Sally McNulty; Alexander Lin; Timothy C Zhu; Jarod C Finlay; Keith Cengel; Virginia Livolsi; Michael Feldman; Rosemarie Mick; Theresa M Busch
Journal:  Oral Oncol       Date:  2016-02-08       Impact factor: 5.337

6.  Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy.

Authors:  Zheng Huang; Qun Chen; Abdus Shakil; Hua Chen; Jill Beckers; Howard Shapiro; Fred W Hetzel
Journal:  Photochem Photobiol       Date:  2003-11       Impact factor: 3.421

7.  Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity.

Authors:  K F Fan; C Hopper; P M Speight; G Buonaccorsi; A J MacRobert; S G Bown
Journal:  Cancer       Date:  1996-10-01       Impact factor: 6.860

8.  Relationship of tumor hypoxia and response to photodynamic treatment in an experimental mouse tumor.

Authors:  B W Henderson; V H Fingar
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

9.  mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma.

Authors:  Colin Hopper; Alexander Kübler; Harry Lewis; I Bing Tan; Graham Putnam
Journal:  Int J Cancer       Date:  2004-08-10       Impact factor: 7.396

Review 10.  Photodynamic therapy in the management of potentially malignant and malignant oral disorders.

Authors:  Waseem Jerjes; Zaid Hamdoon; Colin Hopper
Journal:  Head Neck Oncol       Date:  2012-04-30
View more
  6 in total

Review 1.  Vitamin D and Other Differentiation-promoting Agents as Neoadjuvants for Photodynamic Therapy of Cancer.

Authors:  Edward V Maytin; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2020-04-15       Impact factor: 3.421

2.  Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.

Authors:  John A Roque Iii; Houston D Cole; Patrick C Barrett; Liubov M Lifshits; Rachel O Hodges; Susy Kim; Gagan Deep; Antonio Francés-Monerris; Marta E Alberto; Colin G Cameron; Sherri A McFarland
Journal:  J Am Chem Soc       Date:  2022-04-28       Impact factor: 16.383

Review 3.  The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.

Authors:  Madison Ernst; Alessio Giubellino
Journal:  Biomedicines       Date:  2022-03-31

Review 4.  Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma.

Authors:  Xin-Ying Li; Liu-Chang Tan; Li-Wen Dong; Wan-Qi Zhang; Xiao-Xiao Shen; Xiao Lu; Hong Zheng; Yuan-Gang Lu
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

Review 5.  Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer.

Authors:  Scott C Hester; Maju Kuriakose; Christopher D Nguyen; Srivalleesha Mallidi
Journal:  Photochem Photobiol       Date:  2020-03-05       Impact factor: 3.521

6.  Photodynamic therapy dosimetry using multiexcitation multiemission wavelength: toward real-time prediction of treatment outcome.

Authors:  Monirehalsadat Mousavi; Lilian Tan Moriyama; Clovis Grecco; Marcelo Saito Nogueira; Katarina Svanberg; Cristina Kurachi; Stefan Andersson-Engels
Journal:  J Biomed Opt       Date:  2020-04       Impact factor: 3.170

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.